GATA3 Transcription Factor Abrogates Smad4 Transcription Factor-Mediated Fascin Overexpression, Invadopodium Formation, and Breast Cancer Cell Invasion.

Jianwei Sun,Huifang He,Smitha Pillai,Yin Xiong,Sridevi Challa,Liyan Xu,Srikumar Chellappan,Shengyu Yang

DOI: https://doi.org/10.1074/jbc.m113.506535

2013-01-01

Abstract:Background: Fascin is a pro-metastasis actin bundling protein overexpressed in basal-like breast cancer. Results: GATA3 abrogates TGFβ and Smad4-mediated fascin overexpression by abolishing the binding of Smad4 to fascin promoter. Conclusion: GATA3 is a novel suppressor of the canonical TGFβ-Smad signaling pathway. Significance: These findings provide mechanistic insight into how TGFβ-mediated invasion and metastasis are differentially regulated in different subgroups of breast cancer. Transforming growth factor β (TGFβ) is a potent and context-dependent regulator of tumor progression. TGFβ promotes the lung metastasis of basal-like (but not the luminal-like) breast cancer. Here, we demonstrated that fascin, a pro-metastasis actin bundling protein, was a direct target of the canonical TGFβ-Smad4 signaling pathway in basal-like breast cancer cells. TGFβ and Smad4 induced fascin overexpression by directly binding to a Smad binding element on the fascin promoter. We identified GATA3, a transcription factor crucial for mammary gland morphogenesis and luminal differentiation, as a negative regulator of TGFβ- and Smad4-induced fascin overexpression. When ectopically expressed in basal-like breast cancer cells, GATA-3 abrogated TGFβ- and Smad4-mediated overexpression of fascin and other TGFβ response genes, invadopodium formation, cell migration, and invasion, suggesting suppression of the canonical TGFβ-Smad signaling axis. Mechanistically, GATA3 abrogated the canonical TGFβ-Smad signaling by abolishing interactions between Smad4 and its DNA binding elements, potentially through physical interactions between the N-terminal of GATA3 and Smad3/4 proteins. Our findings provide mechanistic insight into how TGFβ-mediated cell motility and invasiveness are differentially regulated in breast cancer.